Vanguard Personalized Indexing Management LLC Increases Stake in Haleon plc (NYSE:HLN)

Vanguard Personalized Indexing Management LLC boosted its stake in shares of Haleon plc (NYSE:HLN) by 17.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 113,297 shares of the company’s stock after purchasing an additional 17,138 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Haleon were worth $936,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HLN. Cultivar Capital Inc. acquired a new stake in Haleon during the 2nd quarter valued at approximately $40,000. Allspring Global Investments Holdings LLC purchased a new stake in Haleon in the first quarter valued at $43,000. GAMMA Investing LLC grew its position in Haleon by 151.3% during the 1st quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock worth $52,000 after purchasing an additional 3,676 shares during the period. Pinnacle Bancorp Inc. raised its stake in shares of Haleon by 29.8% during the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock valued at $53,000 after buying an additional 1,421 shares during the last quarter. Finally, Hexagon Capital Partners LLC lifted its holdings in shares of Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after buying an additional 2,677 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HLN shares. The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Morgan Stanley raised their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday. Finally, Berenberg Bank started coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Stock Up 1.1 %

HLN stock opened at $10.64 on Tuesday. Haleon plc has a one year low of $7.70 and a one year high of $10.76. The firm has a market cap of $48.56 billion, a PE ratio of 35.45, a PEG ratio of 3.10 and a beta of 0.26. The firm’s 50 day moving average price is $9.80 and its 200-day moving average price is $8.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same period last year, the company earned $0.08 EPS. On average, equities research analysts anticipate that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were given a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is currently 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.